Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Proliferative, phenotypic and functional and molecular characteristics of tumour-infiltrating lymphocytes obtained from unselected patients with malignant melanomas and expanded in vitro in the presence of recombinant interleukin-2.
Melioli G, Guastella M, Semino C, Meta M, Pietra G, Ponte M, Queirolo P, Sertoli MR, Martini L, Reali UM. Melioli G, et al. Among authors: semino c. Melanoma Res. 1994 Apr;4(2):127-33. doi: 10.1097/00008390-199404000-00007. Melanoma Res. 1994. PMID: 8069098
Treatment of stage IIIB non-small-cell lung cancer with surgery followed by infusion of tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study.
Melioli G, Ratto GB, Ponte M, Guastella M, Semino C, Fantino G, Tassara E, Pasquetti W, Mereu C, Merlo F, Reggiardo G, Morasso G, Santi L, Moretta L. Melioli G, et al. Among authors: semino c. J Immunother Emphasis Tumor Immunol. 1996 May;19(3):224-30. doi: 10.1097/00002371-199605000-00007. J Immunother Emphasis Tumor Immunol. 1996. PMID: 8811497
Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: a phase I/II pilot trial. Melanoma Istituto Scientifico Tumori Group.
Queirolo P, Ponte M, Gipponi M, Cafiero F, Peressini A, Semino C, Pietra G, Lionetto R, Vecchio S, Ribizzi I, Melioli G, Sertoli MR. Queirolo P, et al. Among authors: semino c. Ann Surg Oncol. 1999 Apr-May;6(3):272-8. doi: 10.1007/s10434-999-0272-4. Ann Surg Oncol. 1999. PMID: 10340886 Clinical Trial.
123 results